In this article· 13 sectionsClick to collapse

11. Common clinic scenarios
22. Common patient Q&As
33. 30-second takeaway: 8 things to remember
44. What is myopic maculopathy? The Meta-PM grading
55. How was the study done? (8-year prospective cohort)
66. Core result: axial-length change predicts progression
77. The 0.325 mm/year cut-off: how to use it (and not misuse it)
88. Why does axial elongation damage the macula?
99. Study limitations
1010. Taiwan context and NHI notes
1111. Red flags: when a high-myopia child needs prompt care
1212. Conclusion: turning axial length from a «glasses number» into an early-warning tool
13References

Enlarge diagram

Scroll horizontally and vertically to read the diagram. Close Enlarge diagram to restore its original size.

Pediatric high-myopia maculopathy at a glance. ① As axial length increases, the posterior retina thins, the choroid thins, and the sclera remodels; myopic maculopathy is graded by the Meta-PM system from mild to severe: C0 normal → C1 tessellated fundus → C2 diffuse chorioretinal atrophy → C3 patchy atrophy → C4 macular atrophy, plus «plus» lesions (lacquer cracks, Fuchs spot, CNV). Over 8 years, 31.3% of eyes moved to a more severe stage; about 77% of eyes with baseline diffuse atrophy (C2) progressed (36 of 47). ② Prediction model: baseline AL alone predicted 8-year progression at AUC 0.772; adding the first 2-year AL change rate raised it to 0.829 (P=.013), with a high-risk cut-off of ≥0.325 mm/year; the models were adjusted for age and pathologic myopia. ③ Three take-homes: (green) high-myopia children should have regular axial-length measurement plus dilated fundus exams; (yellow) high-risk features = fast axial growth, younger age, very high myopia, existing pathologic myopia; (red) this is a single-centre Han-Chinese study, the model is not externally validated, and the cut-off is a research value not a personal diagnostic line — risk and control decisions should be individualised by your ophthalmologist. Source: Jiang et al. 2026 AJO (Zhongshan, 155 patients / 310 eyes, 8-year follow-up).

1. Common clinic scenarios

'Doctor, my child is already over −7 D in primary school; the prescription keeps climbing and the axial length keeps growing. I know myopia control matters, but what I really worry about is — will his eyes eventually «break down»? Could he go blind like the news says?'

'Doctor, every visit you measure an «axial length» number for my child — what's it for? How is it different from the prescription? What can it tell us?'

'Doctor, I'm highly myopic too and my fundus photo shows «tessellation». Is this hereditary? My child seems fine now — does that mean we don't need to worry?'

All these point to the same thing: what high-myopia families fear most isn't «how many diopters» but whether the eye will reach irreversible maculopathy. The 2026 Zhongshan 8-year follow-up study answered two key questions: (1) what fraction of high-myopia children's maculae progress over 8 years? (2) can short-term axial-length change predict who will progress? (The same team's 4-year results, published in 2024, found progression in about 12% of eyes, with faster axial elongation among the risk factors; Jiang 2024.) This article translates it into clinic language.

2. Common patient Q&As

Q1: How likely is maculopathy progression in 8 years for high-myopia children?

A: In this study, about 1 in 3 eyes (31.3%). Among 310 high-myopia (≤ −6 D) children's eyes followed for 8 years, 97 showed maculopathy progression. The commonest change was a newly appearing tessellated fundus (44.6% of all changes) — the earliest sign of myopic maculopathy, reflecting choroidal thinning that lets the underlying vessels show through. This reminds us high myopia isn't just «blurry vision needing thicker glasses» — structural fundus changes genuinely accumulate from childhood into early adulthood. To be clear, though: progression in 8 years does NOT equal blindness — the commonest were early changes (normal → tessellated); few reached severe atrophy.

Q2: Why measure «axial length»? How is it different from the prescription?

A: Axial length is the eye's actual front-to-back length — a more stable, objective progression marker than refraction. Refraction (spherical equivalent) is affected by the cornea, lens accommodation, and the moment of testing; axial length (measured directly by optical biometry) reflects how much the eye has truly elongated. This study's key finding: adding the first 2-year axial-length change rate raised the accuracy (AUC) of predicting 8-year maculopathy progression from 0.772 to 0.829 — meaning how fast the eye elongates itself carries predictive information about future complications, not just a basis for new glasses. The International Myopia Institute's 2025 instrumentation report likewise lists axial-length measurement among the key tools for detecting and monitoring myopia progression (Jones 2025).

Q3: What does the «0.325 mm/year» cut-off mean? Does exceeding it guarantee trouble?

A: It's a statistically derived reference line to separate high vs low risk — not a diagnostic «cross it and you go blind» threshold. The researchers used Youden's index to find the axial-growth speed that best distinguished «will progress vs won't»: about 0.325 mm/year. Read it as: children whose eyes grow faster than this in the first 2 years are, on average, a group needing closer attention. But three caveats: (1) it's a population-level risk boundary, not a personal guarantee; (2) it comes from a single-centre, specific population; Taiwanese children may differ; (3) it's a tool to identify who should be controlled more aggressively, not a number to scare yourself or self-diagnose with. Whether you are truly high-risk and whether to adjust treatment is for your ophthalmologist to judge holistically.

Q4: Which children are most at risk? Are there «high-risk features»?

A: The study highlights several high-risk features. (1) Fast axial growth: high 2-year AL change rate (≥0.325 mm/yr). (2) High myopia at a younger age: progressors were actually younger on average (12.9 vs 14.0 y) — earlier high myopia means more remaining growth years for the eye to keep elongating. (3) Deeper refraction, longer axis: progressors had deeper baseline SE (−10.7 vs −8.5 D) and longer AL (27.7 vs 26.7 mm). (4) Atrophic change at baseline: about 77% of eyes with baseline diffuse atrophy (C2) progressed over 8 years (36 of 47). (5) Lacquer cracks appearing during follow-up: present in 15 eyes at 8 years, a lesion that needs close follow-up. The more features present, the greater the need for aggressive control and intensive follow-up.

Q5: So how do I «control» it? Did this study say which method is best?

A: This is a «prediction» study, not a «treatment comparison» — it did not compare which control method is best. In fact, to cleanly observe natural progression, the study deliberately EXCLUDED children using orthokeratology, defocus lenses, atropine, or repeated low-level red-light therapy. So its message is «who is high-risk and needs close watching», not «which drug to use». Myopia-control tools (low-dose atropine, ortho-K, special optical-design lenses, outdoor time) each have their own evidence and indications, chosen by the ophthalmologist based on the child's age, refraction, axial-progression speed, and adherence. Read alongside myopia-control articles, the logic is: use axial length to flag high risk → then the doctor selects the appropriate control method.

Q6: Isn't maculopathy an «old people's» disease? How can a child have it?

A: «Myopic maculopathy» differs from age-related macular degeneration (AMD) — its root cause is axial elongation, and it can begin in childhood. Myopic maculopathy does become more common with age (e.g. a Singapore study of adults aged 40+, Wong 2018), but research shows its pathological changes often quietly begin in childhood and adolescence, during rapid ocular growth. A Japanese study with 20+ years of follow-up (Yokoi 2016) found that high-myopia children who already had peripapillary diffuse chorioretinal atrophy were more likely to develop pathologic myopia in adulthood. In this study, participants averaged about 22 years old at the 8-year visit, and 15 eyes already had lacquer cracks. So the point is: a high-myopia child's fundus shouldn't be taken lightly just because «vision is still okay now» — structural changes may already be accumulating.

Q7: How often should high-myopia children be checked, and with what tests?

A: Frequency and tests are set by the ophthalmologist based on individual risk, but this study highlights two key examinations. The study did a full assessment every 2 years, including: (1) axial length (optical biometry) — to track elongation speed; (2) dilated macula and optic-disc fundus photography — to grade progression by Meta-PM; plus corrected acuity, IOP, and refraction. In practice, for high myopia or fast axial progression the doctor may shorten the interval (e.g. every 6–12 months) and add OCT as needed. Key message: a high-myopia child's visit shouldn't be just «check the prescription and change glasses» — it should include axial length and a dilated fundus exam to catch early macular changes.

3. 30-second takeaway: 8 things to remember

📋 Pediatric high-myopia maculopathy: 8 things to remember

1-in-3 progress in 8 years: 155 high-myopia children, 310 eyes, 31.3% maculopathy progression over 8 years (Zhongshan cohort)
Commonest = new tessellated fundus (44.6%) — earliest maculopathy sign, reflecting choroidal thinning
2-year AL change predicts 8-year progression: AUC 0.772 → 0.829 when added (P=.013)
High-risk cut-off: AL ≥0.325 mm/year — a population boundary, not a personal diagnosis
Axial length is more objective than refraction: reflects true elongation; a key monitoring marker for high-myopia children (IMI 2025)
High-risk features: fast axial growth, young-onset high myopia, very deep SE, baseline diffuse atrophy (C2, about 77% progressed), lacquer cracks
A «prediction» study, not «treatment comparison»: deliberately excluded atropine/ortho-K/defocus-lens/red-light users; says nothing about which control is best
Extrapolate cautiously: single centre, Han-Chinese children, model not externally validated; individual assessment of Taiwanese children stays with your ophthalmologist

4. What is myopic maculopathy? The Meta-PM grading

Myopic maculopathy (MM) is high myopia's most important and feared complication — a major cause of visual impairment and blindness, especially in East Asia (Ohno-Matsui 2016). Its root mechanism: the axial length (front-to-back length of the eye) elongates excessively, mechanically stretching and thinning the retina, choroid, and sclera at the posterior pole (where the macula sits), causing progressive structural degeneration. Internationally it is graded into five categories by the Meta-analysis for Pathologic Myopia (Meta-PM) system:

Scroll horizontally to read the table. With a keyboard, focus the table area and use the arrow keys.

Category	Fundus change	Meaning
C0	No myopic retinal change	Normal
C1	Tessellated fundus	Earliest; choroid thinning begins
C2	Diffuse chorioretinal atrophy	Enters «pathologic myopia» range
C3	Patchy chorioretinal atrophy	Focal full atrophy; vision affected
C4	Macular atrophy	Most severe; severe central vision loss

Beyond these five, three «plus» lesions warrant special vigilance: lacquer cracks (LCs) — mechanical breaks in Bruch's membrane; Fuchs spot; and choroidal neovascularization (CNV) — which bleeds and causes acute vision loss. The study defined pathologic myopia (PM) as worse than C1 or the presence of any plus lesion.

5. How was the study done? (8-year prospective cohort)

This was a hospital-based prospective cohort at Zhongshan Ophthalmic Center, Guangzhou. Enrolled 2011–2012: children/adolescents aged 7–17 with high myopia (SE ≤ −6.0 D), followed every 2 years for 8 years. Ultimately 155 participants / 310 eyes completed the full 8-year follow-up and were analysed. Each visit measured: axial length (Lenstar optical biometry; IOLMaster if >32 mm), cycloplegic refraction, corrected acuity, IOP, and dilated macula- and disc-centred fundus photography. Fundus images were graded by senior ophthalmologists trained in Meta-PM, with good inter-grader agreement (kappa 0.73–0.84). To cleanly observe natural progression, children using orthokeratology, defocus lenses, atropine, repeated low-level red-light therapy, or who had refractive/intraocular surgery were excluded.

Over 8 years, mean age rose from 13.6 to 22.0; axial length increased from 27.03 to 28.01 mm; SE deepened from −9.18 to −11.77 D. Even into early adulthood, high myopia kept progressing.

6. Core result: axial-length change predicts progression

The study used GEE logistic regression to identify predictors of 8-year maculopathy progression and compared model accuracy (area under the ROC curve, AUC; closer to 1.0 = better):

Scroll horizontally to read the table. With a keyboard, focus the table area and use the arrow keys.

Prediction model	Factors	AUC
Model 1 (baseline AL)	age + PM + baseline AL	0.772
Model 2 (+AL change)	Model 1 + 2-year AL change rate	0.829
Model 3 (baseline SE)	age + PM + baseline SE	0.764
Model 4 (+SE change)	Model 3 + 2-year SE change rate	0.793

Three points: (1) Adding the «2-year AL change rate» markedly improved prediction (0.772 → 0.829, P=.013) — the paper's key message: short-term axial change carries independent information about long-term complications. (2) SE-based versions (Models 3, 4) were slightly less accurate than AL-based ones, again supporting axial length as the better progression marker. (3) After bootstrap internal validation, the optimism-corrected AUC was still 0.821 with minimal optimism (0.008), indicating internal stability. After adjustment for age and pathologic myopia, baseline AL (OR 1.62) and the 2-year AL change rate (OR 1.62) were both significant predictors.

7. The 0.325 mm/year cut-off: how to use it (and not misuse it)

Using Youden's index on the ROC curve, the axial-growth speed that best separated «will progress vs won't» was about 0.325 mm/year. Its correct use: a reference line to flag a child into the «needs closer attention» group. But it is easily misused — remember:

⚠️ Reading the cut-off correctly

A population boundary, not a personal guarantee: above it doesn't mean certain progression; below it isn't absolute safety.
A research value, not a diagnostic line: from a single-centre specific population; not for self-interpretation or panic.
A triage tool, not a treatment order: it helps flag who needs more aggressive control/follow-up, but the method and interval are the ophthalmologist's call.
Normal children's eyes grow anyway: axial elongation is natural during development; the point is whether it's «too fast for a high-myopia child», judged by the doctor against age and baseline.

8. Why does axial elongation damage the macula?

Think of the eye as a balloon: as the axial (front-to-back) length is «blown» longer, the wall at the posterior pole stretches thinner. This mechanical stretch triggers a cascade:

🔬 Axial elongation → maculopathy mechanism chain

Scleral remodeling and thinning: the eye wall's (scleral) collagen is rearranged and thinned, losing support, so the posterior pole bulges backward (sometimes forming a posterior staphyloma).
Choroidal thinning: the choroid is the vascular layer feeding the outer retina; once thinned, blood flow and oxygen drop, and the outer retina becomes ischaemic and degenerates — the basis of tessellation progressing to atrophy.
Mechanical breaks in Bruch's membrane (lacquer cracks): stretching the RPE–Bruch's–choriocapillaris complex to its limit causes cracks (lacquer cracks), a launchpad for choroidal neovascularization (CNV) — and CNV bleeding can cause acute central vision loss.

This chain explains why «fast axial growth» is such a strong predictor: rapid elongation = rapid stretching of posterior-pole tissue = accelerated degeneration. So a core goal of controlling myopia progression is to slow axial elongation, reducing future maculopathy risk at its source.

9. Study limitations

⚠️ 5 limitations to remember

Single centre, specific population: one Guangzhou centre, mainly Han-Chinese children; Taiwanese children are similar but extrapolation needs caution.
Model not externally validated: only internal bootstrap validation so far; the cut-off and AUC may differ in other populations.
Limited fundus-photo coverage: photos were centred on the macula and optic disc, so changes outside the field (such as posterior staphyloma) may not be fully assessed.
Non-blinded grading: graders knew baseline vs follow-up, a theoretical classification-bias risk (minimised by inter-rater agreement and standardisation).
Follow-up rate not optimal: long-term attrition is inevitable (~36% finally analysed); participants and non-participants did not differ significantly at baseline except in sex, but selection bias cannot be fully ruled out.

10. Taiwan context and NHI notes

⚠️ Costs & coverage — confirm with your care team and the latest NHIA rules

Taiwan is also a high-myopia region: East-Asian children have among the world's highest myopia and high-myopia rates, so this Han-Chinese study is highly relevant to Taiwanese families — but individual assessment stays with your ophthalmologist.
Costs/coverage of myopia-control treatments: under the Taiwan NHI drug reimbursement rules (updated 2026-10-22), section 14.9.6, low-dose atropine eye drops (0.1–0.5 mg/mL, i.e. 0.01%–0.05%) are covered for children and adolescents aged 18 or younger, in pack sizes of at least 3.5 mL, one bottle per 4 weeks, with no pre-approval required — discuss the details with your doctor. Ortho-K, special optical-design lenses and red-light therapy each have different and changing NHI/self-pay status; refer to your hospital's pre-service notice and the latest NHIA announcements. No claims are made here about these items.
NHI coverage if myopic choroidal neovascularization (myopic CNV) develops: the standard treatment is intravitreal anti-VEGF injection. Under the Taiwan NHI drug reimbursement rules (updated 2026-10-22), section 14.9.2 item (5), ranibizumab or aflibercept (aflibercept 8 mg is excluded for this indication) is covered when myopia exceeds 600 degrees (−6.00 D), axial length is over 26 mm, testing shows active CNV leakage or intraretinal/subretinal fluid, and best-corrected visual acuity is 0.05–0.5. An ophthalmologist must apply for prior authorization; coverage is a single application of up to 3 injections per eye. Patients with a history of stroke, or intraocular steroid treatment within the past 3 months, are not eligible. Your ophthalmologist will assess whether you qualify.
Axial-length measurement and fundus exams: not every clinic has optical biometry; for a highly myopic child wanting regular axial-length and dilated-fundus monitoring, ask your clinic about equipment and scheduling.
Outdoor time: Taiwan's Health Promotion Administration «3010120» guidance recommends a 10-minute break after every 30 minutes of near work and at least 120 minutes outdoors daily; more outdoor time is a well-evidenced, almost cost-free, generally healthy myopia-prevention strategy worth building as a habit early. The evidence, however, is mainly for delaying myopia onset; whether it slows progression in children who are already myopic (including high myopes) is unclear (Xiong 2017; IMI 2025), so it does not replace myopia control recommended by the eye doctor.

11. Red flags: when a high-myopia child needs prompt care

🚨 Red flags for high-myopia children

Sudden flashes, a surge of new floaters, or a curtain/shadow over part of the vision — warns of retinal detachment (high-myopia high risk); seek same-day care
Central distortion/warping, or a blurred dark patch in the centre — possible CNV bleeding or maculopathy progression
Marked unilateral vision drop over a short time — don't assume it's «just more myopia»; get a prompt fundus exam
Markedly accelerated axial growth at follow-up — not an emergency, but discuss adjusting the myopia-control strategy with your doctor

The first three are acute warning signs that can threaten vision — seek same-day care; even without symptoms, high-myopia children should attend regular axial-length and dilated-fundus follow-up.

12. Conclusion: turning axial length from a «glasses number» into an early-warning tool

The most valuable contribution of this 8-year study is elevating «axial length» from a number that merely sets glasses power into an early tool for predicting future maculopathy. It tells us two practical things: (1) about one-third of high-myopia children's maculae change within 8 years — this is not a distant old-age disease; (2) simply watching how fast axial length grows in the first 2 years can fairly accurately flag future high-risk children.

Three practical messages for parents: (1) High-myopia children must have regular follow-up that includes axial length and a dilated fundus exam — not just a refraction and new glasses. (2) Fast axial growth is a warning sign — it means more aggressive myopia control is warranted, but the method is for the ophthalmologist to decide. (3) The earlier you start, the more you protect the macula — younger children have many growth years ahead, so controlling axial elongation early is buying insurance for vision decades later. Controlling myopia ultimately protects not just «how clearly you see» but «whether the fundus breaks down».

📚 HsiaoEye Related Articles — Pediatric Myopia / Retina

Monitoring myopia: SER or axial length? — Why axial length is the key metric to track
Are DIMS lenses effective? — A tool to slow axial elongation
8 pediatric myopia myths — Atropine, ortho-K, red light, outdoors
6 Floater Red Flags — Retinal detachment risk in high myopia

References

Jiang F, Wang L, Ding X, He M, Zeng J, Li Z. Short-Term Axial Length Changes Predict Progression of Myopic Maculopathy in Pediatric High Myopia. Am J Ophthalmol. 2026;287:188–197. doi:10.1016/j.ajo.2026.03.022
Ohno-Matsui K, Kawasaki R, Jonas JB, et al; META-analysis for Pathologic Myopia (META-PM) Study Group. International photographic classification and grading system for myopic maculopathy. Am J Ophthalmol. 2015;159(5):877–883.e7. doi:10.1016/j.ajo.2015.01.022
Ohno-Matsui K, Lai TYY, Lai CC, Cheung CMG. Updates of pathologic myopia. Prog Retin Eye Res. 2016;52:156–187.
Fang Y, Yokoi T, Nagaoka N, et al. Progression of myopic maculopathy during 18-year follow-up. Ophthalmology. 2018;125(6):863–877.
Tideman JWL, Snabel MCC, Tedja MS, et al. Association of axial length with risk of uncorrectable visual impairment for Europeans with myopia. JAMA Ophthalmol. 2016;134(12):1355–1363.
Wong YL, Sabanayagam C, Ding Y, et al. Prevalence, risk factors, and impact of myopic macular degeneration on visual impairment and functioning among adults in Singapore. Invest Ophthalmol Vis Sci. 2018;59(11):4603–4613.
Bullimore MA, Brennan NA. Myopia control: why each diopter matters. Optom Vis Sci. 2019;96(6):463–465.
Jiang F, Wang D, Xiao O, et al. Four-year progression of myopic maculopathy in children and adolescents with high myopia. JAMA Ophthalmol. 2024;142(3):180–186. doi:10.1001/jamaophthalmol.2023.6319
Yokoi T, Jonas JB, Shimada N, et al. Peripapillary diffuse chorioretinal atrophy in children as a sign of eventual pathologic myopia in adults. Ophthalmology. 2016;123(8):1783–1787. doi:10.1016/j.ophtha.2016.04.029
Jones D, Chow A, Fadel D, et al. IMI—Instrumentation for myopia management. Invest Ophthalmol Vis Sci. 2025;66(9):7. doi:10.1167/iovs.66.9.7
Xiong S, Sankaridurg P, Naduvilath T, et al. Time spent in outdoor activities in relation to myopia prevention and control: a meta-analysis and systematic review. Acta Ophthalmol. 2017;95(6):551–566. doi:10.1111/aos.13403
Ashby R, Harb EN, Ostrin LA, et al. IMI: The role of light in refractive development and myopia: evidence from animal and human studies. Invest Ophthalmol Vis Sci. 2025;66(15):5. doi:10.1167/iovs.66.15.5
衛生福利部國民健康署。〈兒童護眼運動國健署推動3010120 幫助孩子從小存好視力〉（新聞稿），2022-07-08 發布、2022-09-26 更新。

Frequently asked questions

How likely is maculopathy progression in 8 years for high-myopia children?

In this 8-year study of 310 high-myopia children's eyes, about one-third of eyes (31.3%, 97 eyes) showed maculopathy progression, most commonly a newly appearing tessellated fundus (44.6%). To be clear, early changes such as a tessellated fundus do not equal blindness; only a few reached severe atrophy.

Why measure axial length, and how is it different from the prescription?

Axial length is the eye's actual front-to-back length, measured directly by optical biometry; it reflects true elongation and is a more stable, objective progression marker than refraction, which is affected by the cornea, lens accommodation, and the moment of testing. This study found that adding the first 2-year axial-length change rate raised the accuracy (AUC) of predicting 8-year maculopathy progression from 0.772 to 0.829.

What does the 0.325 mm/year cut-off mean, and does exceeding it guarantee trouble?

This is a reference line found with Youden's index for the axial-growth speed that best separated progressors from non-progressors, about 0.325 mm/year. It is a population-level risk boundary, not a personal diagnostic threshold that means blindness if crossed. It comes from a single-centre, specific population, so Taiwanese children may differ; whether you are truly high-risk and whether to adjust treatment is for your ophthalmologist to judge holistically.

Which high-myopia children are most at risk, and what are the high-risk features?

The study highlights several high-risk features: fast axial growth in the first 2 years (>=0.325 mm/year), high myopia at a younger age (progressors averaged 12.9 years), very deep refraction and longer axis (progressors averaged about -10.7 D and 27.7 mm), baseline diffuse atrophy (about 77% progressed), and lacquer cracks appearing during follow-up. The more features present, the greater the need for aggressive control and more intensive follow-up.

Did this study say which myopia-control method is best?

No. This is a prediction study, not a treatment-comparison study; to cleanly observe natural progression, it deliberately excluded children using orthokeratology, defocus lenses, atropine, or repeated low-level red-light therapy. Its message is to identify who is high-risk and needs close monitoring, not which drug to use. Each myopia-control tool has its own evidence and indications and should be chosen by the ophthalmologist based on the child's age, refraction, axial-progression speed, and adherence.

How often should high-myopia children be checked, and with what tests?

Frequency and tests are set by the ophthalmologist based on individual risk. This study did a full assessment every 2 years, with key items being axial length (optical biometry) to track elongation speed, and dilated macula and optic-disc fundus photography graded by Meta-PM, plus corrected acuity, intraocular pressure, and refraction. In practice, if refraction or axial length progresses fast, the doctor may shorten the interval to every 6 to 12 months and add OCT as needed.

Childhood High Myopia: In 8 Years Maculopathy Worsened in ~1/3 of Eyes